2 weeks Ago By ABMN Staff
Revelation Biosciences, Inc. ( NASDAQ:REVB – Free Report ) – Equities researchers at Zacks Small Cap lifted their FY2024 EPS estimates for shares of Revelation Biosciences in a research note issued on Monday, November 11th. Zacks Small Cap analyst B.
Sorensen now forecasts that the company will earn ($9.38) per share for the year, up from their prior forecast of ($16.32).
The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share. Zacks Small Cap also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.
95) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.
80) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.25) EPS.
Revelation Biosciences Trading Down 8.1 % Shares of NASDAQ:REVB opened at $0.84 on Wednesday.
The company has a 50 day moving average of $0.85 and a 200-day moving average of $1.42.
The firm has a market cap of $1.37 million, a P/E ratio of -0.05 and a beta of 0.
15. Revelation Biosciences has a twelve month low of $0.70 and a twelve month high of $25.
26. About Revelation Biosciences Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
See Also Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
